Highlights Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 13/05/2026 pm IST			5-day change	1st Jan Change
1,684.00 ^DKK	-1.66%		-4.24%	-16.92%

12/05	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
11/05	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

Highlights

08/05	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Genmab Q1 Net Profit Falls, Revenue Rises	MT
07/05	Genmab reports Q1 operating profit of $180 million	RE
14/04	Genmab Posts Higher Darzalex Net Sales in Q1	MT
14/04	Genmab Q1 Darzalex net sales at $3,964 mln	RE
13/04	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
16/03	Genmab Wraps Up Share Repurchase Program	MT
16/03	Genmab completed share buy-back program on March 13	RE
16/03	H Lundbeck A S Presents New Phase 1b Data for Lu Af28996 and Advances Pipeline in Movement Disorders	CI
19/02	BofA Bullish on Genmab's FY26 Catalyst Path; Buy Rating Maintained	MT
18/02	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
18/02	Genmab FY oper profit up at $1,065 mln	RE
18/02	Genmab announces initiation of share buy-back program	RE
17/02	Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued	MT
17/02	(GMAB) Genmab Expects 2026 Revenue Range $4.07B - $4.40B, vs. FactSet Est of $4.32B	MT
17/02	Genmab A/S Reports Earnings Results for the Full Year Ended December 31, 2025	CI
17/02	Genmab Provides Earnings Guidance for the Full Year 2026	CI
04/02	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT
21/01	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
29/12	Genmab Discontinues Development of Tumor Treatment Acasunlimab	MT
29/12	Genmab A/S Reaffirms Earnings Guidance for the Year 2025	CI